TP53 and carcinoma: They noticed that patients with carcinomas containing a wild-type p53 did not benefit as much as the patients with a mutated TP53 from an increase in the number of weekly fractions (i.e. a reduction in the overall treatment time), as judged by local control at T-site, disease-specific or crude survival [39].